Skip to content
  • About Us
    • Management
    • Board of Directors
    • Clinical and Scientific Advisory Board
  • Careers
  • Lead Technology
  • Publications
  • Investors
  • Contact Us
Menu
  • About Us
    • Management
    • Board of Directors
    • Clinical and Scientific Advisory Board
  • Careers
  • Lead Technology
  • Publications
  • Investors
  • Contact Us
Search
Close
Vasomune Therapeutics Appoints Meenu Chhabra to its Board of Directors

Vasomune Therapeutics Appoints Meenu Chhabra to its Board of Directors

  • Post author:Shahid Ahmad
  • Post published:March 24, 2020
  • Post category:Uncategorized

Vasomune Therapeutics Appoints Meenu Chhabra to its Board of Directors  Industry Leader Joins Vasomune’s Board of Directors as the Company Transitions to Clinical Development of AV-001 for the treatment of COVID-19/Pathogen-induced…

Continue Reading Vasomune Therapeutics Appoints Meenu Chhabra to its Board of Directors

The COVID-19 Coronavirus Leads to Acute Respiratory Distress Syndrome (ARDS)

  • Post author:Shahid Ahmad
  • Post published:March 20, 2020
  • Post category:Uncategorized

An article in USA Today describes certain risks associated with contraction of the COVID-19 coronavirus, specifically the major cause of lethality being Acute Respiratory Distress Syndrome (ARDS).  The article can…

Continue Reading The COVID-19 Coronavirus Leads to Acute Respiratory Distress Syndrome (ARDS)

Recent Posts

  • AV-001 Receives Positive Recommendation from the IDSMB for AV001-004 Phase 2a Study
  • Vasomune and AnGes Announce First Patient Enrolled in Phase 2a Clinical Study Evaluating AV-001 for the Treatment of Severe COVID-19 Disease
  • Vasomune Announces Government Financial Support for the Development of COVID-19 Therapeutic
  • Vasomune Announces Preliminary Positive Phase 1 Clinical Trial Results for Vascular Normalization Therapy
  • Vasomune is Pleased to Announce the Government of Canada’s Investment in AV-001 Targeting COVID-19

Recent Comments

    Archives

    • November 2023
    • January 2022
    • November 2021
    • March 2021
    • December 2020
    • November 2020
    • August 2020
    • May 2020
    • March 2020
    • February 2020
    • January 2020
    • August 2018
    • December 2017
    • June 2015

    Categories

    • Press Release
    • Uncategorized

    Meta

    • Log in
    • Entries feed
    • Comments feed
    • WordPress.org

    About

    Vasomune Therapeutics is a private biotechnology company developing the next generation of medications to harness the body’s ability to defend against illness by modifying cellular response to disease.

    Vasomune Therapeutics 2020 © All Rights Reserved.